Nomelcitinib (D-2570) vs zasocitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Nomelcitinib (D-2570)

Developed by InventisBio

Phase 3 in PsoriasisSmall molecule (oral TYK2 JH2 pseudokinase-domain inhibitor)
Partial signal

NCT06278350 · Phase 2 · completed

The study randomized 161 participants with moderate to severe plaque psoriasis to three D-2570 dose groups or placebo, with participants, care providers and investigators masked. The primary endpoint, PASI 75 at week 12, was met in all three dose groups versus placebo (at least 85% vs 12.5%, p<0.001), per the sponsor's release and the peer-reviewed publication. The trial is mid-sized and 12 weeks long, so durability and safety beyond week 12 are not established.

Next expected readout: July 2027 · NCT07326813 (registry estimate)

Reported efficacy

Percentage of subjects with at least 75% improvement in PASI (Day 1-Day 85): Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) (met)

Result source: NCT06278350

zasocitinib

Developed by Takeda Pharmaceutical Company

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06108544 · Phase 3 · completed

This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07752108 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib. (met)

Result source: NCT06973291

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNomelcitinib (D-2570)zasocitinib
PASI 75—Trial running · NCT0713060467.3% vs 5.8%+61.5 vs placebo30 mg · wk 12 · n 52NCT04999839
4 other results
  • 67.9% vs 5.8% 15 mg · wk 12 · n 53 · Phase 2 · primary NCT04999839
  • 44.2% vs 5.8% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT04999839
  • 18% vs 5.8% 2 mg · wk 12 · n 50 · Phase 2 · primary NCT04999839
  • 75.7% vs 12.1% wk 16 · Phase 3 · primary NCT06088043
PASI 90—Trial running · NCT0713060446.2% vs 0%+46.2 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 45.3% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 21.2% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 8% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
PASI 100—Trial running · NCT0713060432.7% vs 0%+32.7 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 15.1% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 9.6% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 2% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
sPGA 0/1—Trial running · NCT0713060451.9% vs 3.8%+48.1 vs placebo30 mg · wk 12 · n 52NCT04999839
5 other results
  • 49.1% vs 3.8% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 26.9% vs 3.8% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 10% vs 3.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
  • 69.2% vs 12.6% wk 16 · Phase 3 · primary NCT06108544
  • 71.4% vs 10.7% wk 16 · Phase 3 · primary NCT06088043
DLQI, change—Trial running · NCT07130604-8.9 vs -4.9−4 vs placebo30 mg · wk 12 · n 47NCT04999839
3 other results
  • -8.5 vs -4.9 15 mg · wk 12 · n 46 · Phase 2 · secondary NCT04999839
  • -7.9 vs -4.9 5 mg · wk 12 · n 47 · Phase 2 · secondary NCT04999839
  • -5.3 vs -4.9 2 mg · wk 12 · n 43 · Phase 2 · secondary NCT04999839

PASI 75

Nomelcitinib (D-2570)
—Trial running · NCT07130604
zasocitinib
67.3% vs 5.8%+61.5 vs placebo30 mg · wk 12 · n 52NCT04999839
4 other results
  • 67.9% vs 5.8% 15 mg · wk 12 · n 53 · Phase 2 · primary NCT04999839
  • 44.2% vs 5.8% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT04999839
  • 18% vs 5.8% 2 mg · wk 12 · n 50 · Phase 2 · primary NCT04999839
  • 75.7% vs 12.1% wk 16 · Phase 3 · primary NCT06088043

PASI 90

Nomelcitinib (D-2570)
—Trial running · NCT07130604
zasocitinib
46.2% vs 0%+46.2 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 45.3% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 21.2% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 8% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839

PASI 100

Nomelcitinib (D-2570)
—Trial running · NCT07130604
zasocitinib
32.7% vs 0%+32.7 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 15.1% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 9.6% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 2% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839

sPGA 0/1

Nomelcitinib (D-2570)
—Trial running · NCT07130604
zasocitinib
51.9% vs 3.8%+48.1 vs placebo30 mg · wk 12 · n 52NCT04999839
5 other results
  • 49.1% vs 3.8% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 26.9% vs 3.8% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 10% vs 3.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
  • 69.2% vs 12.6% wk 16 · Phase 3 · primary NCT06108544
  • 71.4% vs 10.7% wk 16 · Phase 3 · primary NCT06088043

DLQI, change

Nomelcitinib (D-2570)
—Trial running · NCT07130604
zasocitinib
-8.9 vs -4.9−4 vs placebo30 mg · wk 12 · n 47NCT04999839
3 other results
  • -8.5 vs -4.9 15 mg · wk 12 · n 46 · Phase 2 · secondary NCT04999839
  • -7.9 vs -4.9 5 mg · wk 12 · n 47 · Phase 2 · secondary NCT04999839
  • -5.3 vs -4.9 2 mg · wk 12 · n 43 · Phase 2 · secondary NCT04999839
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Nomelcitinib (D-2570)
Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) NCT06278350 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Nomelcitinib (D-2570): 0 of 4 rows · zasocitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriczasocitinib
Dropout rate
9.6%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
13.2%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
13.5%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
16%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.9%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
1.9%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
1.9%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
2%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Serious AEs
0%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
1.9%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
30 mga
covid-19 13.5% (placebo 1.9%)
blood creatine phosphokinase increased 5.8% (placebo 3.8%)
dermatitis acneiform 5.8% (placebo 0%)
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
15 mg
covid-19 11.3% (placebo 1.9%)
acne 5.7% (placebo 0%)
blood creatine phosphokinase increased 5.7% (placebo 3.8%)
NCT04999839 · Phase 2 · registry result, not featured evidence
5 mg
covid-19 7.7% (placebo 1.9%)
lymphocyte count decreased 5.8% (placebo 0%)
blood creatine phosphokinase increased 3.8% (placebo 3.8%)
NCT04999839 · Phase 2 · registry result, not featured evidence
2 mg
covid-19 12% (placebo 1.9%)
alanine aminotransferase increased 6% (placebo 0%)
diarrhoea 6% (placebo 1.9%)
NCT04999839 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

zasocitinib

PASI 75 67.3% (n=52) vs 5.8% (n=52) placebo @ 12wk30 mg
responder rate · % of participants
NCT04999839 · Phase 2 · registry result, not featured evidence
show 4 more results
67.9% (n=53) vs 5.8% (n=52) placebo @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
44.2% (n=52) vs 5.8% (n=52) placebo @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
18% (n=50) vs 5.8% (n=52) placebo @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
75.7% vs 12.1% placebo @ 16wk
NCT06088043 · Phase 3 · sponsor-reported, not registry data
sPGA 0/1 51.9% (n=52) vs 3.8% (n=52) placebo @ 12wk30 mg
responder rate · % of participants
NCT04999839 · Phase 2 · registry result, not featured evidence
show 5 more results
49.1% (n=53) vs 3.8% (n=52) placebo @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
26.9% (n=52) vs 3.8% (n=52) placebo @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
10% (n=50) vs 3.8% (n=52) placebo @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
69.2% vs 12.6% placebo @ 16wk
NCT06108544 · Phase 3 · sponsor-reported, not registry data
71.4% vs 10.7% placebo @ 16wk
NCT06088043 · Phase 3 · sponsor-reported, not registry data
PASI 90 46.2% (n=52) vs 0% (n=52) placebo @ 12wk30 mg
responder rate · % of participants
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
45.3% (n=53) vs 0% (n=52) placebo @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
21.2% (n=52) vs 0% (n=52) placebo @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
8% (n=50) vs 0% (n=52) placebo @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
PASI 100 32.7% (n=52) vs 0% (n=52) placebo @ 12wk30 mg
responder rate · % of participants
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
15.1% (n=53) vs 0% (n=52) placebo @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
9.6% (n=52) vs 0% (n=52) placebo @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
2% (n=50) vs 0% (n=52) placebo @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
DLQI -8.9 vs -4.9 placebo score @ 12wk30 mg
absolute change · score
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
-8.5 vs -4.9 placebo score @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
-7.9 vs -4.9 placebo score @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
-5.3 vs -4.9 placebo score @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nomelcitinib (D-2570)'s landscape · zasocitinib's landscape